id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2015-D-2818-0044,FDA,FDA-2015-D-2818,"Rare Diseases: Considerations for the Development of Drugs and Biological
Products; Guidance for Industry; Availability",Notice,Notice of Availability,2023-12-26T05:00:00Z,2023,12,2023-12-26T05:00:00Z,,2023-12-26T14:43:28Z,2023-28310,0,0,0900006486359d43
FDA-2015-D-2818-0045,FDA,FDA-2015-D-2818,Rare Diseases: Considerations for the Development of Drugs and Biological Products; Guidance for Industry - Final Guidance,Other,Guidance,2023-12-26T05:00:00Z,2023,12,2023-12-26T05:00:00Z,,2025-12-31T10:00:23Z,,1,0,090000648635a545
FDA-2015-D-2818-0022,FDA,FDA-2015-D-2818,"Rare Diseases: Common Issues in Drug Development; Draft Guidance for
Industry; Availability",Notice,Notice of Availability,2019-02-01T05:00:00Z,2019,2,2019-02-01T05:00:00Z,2019-04-03T03:59:59Z,2019-04-03T01:02:46Z,2019-00677,0,0,0900006483a32ad2
FDA-2015-D-2818-0023,FDA,FDA-2015-D-2818,"Rare Diseases: Common Issues in Drug Development; Draft Guidance for
Industry; Availability",Other,Guidance,2019-02-01T05:00:00Z,2019,2,2019-02-01T05:00:00Z,2019-04-03T03:59:59Z,2023-12-26T14:48:43Z,,0,0,0900006483a33187
FDA-2015-D-2818-0001,FDA,FDA-2015-D-2818,"Rare Diseases: Common Issues in Drug Development; Draft Guidance for
Industry; Availability",Notice,Notice of Availability,2015-08-17T04:00:00Z,2015,8,2015-08-17T04:00:00Z,2015-10-17T03:59:59Z,2015-10-17T01:30:18Z,2015-20235,0,0,0900006481c24984
FDA-2015-D-2818-0002,FDA,FDA-2015-D-2818,Draft Guidance for  Rare Diseases: Common Issues in Drug Development Guidance for Industry,Other,Guidance,2015-08-17T04:00:00Z,2015,8,2015-08-17T04:00:00Z,,2019-08-21T18:45:44Z,,0,0,0900006481c25389